Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 167 Carcinoma, Non-Small-Cell Lung 111 Lung Neoplasms 54 Hodgkin Disease 22 Neoplasm Metastasis 17 Recurrence 15 Lymphoma 15 Triple Negative Breast Neoplasms 14 Neoplasms 14 Prostatic Neoplasms 10 Adenocarcinoma of Lung 10 Sarcoma 9 Rhabdomyosarcoma 9 Uterine Cervical Neoplasms 8 Lymphoma, Non-Hodgkin 8 Lymphoma, Large B-Cell, Diffuse 6 Small Cell Lung Carcinoma 5 Ovarian Neoplasms 5 Mesothelioma, Malignant 5 Breast Neoplasms, Male 5 Brain Neoplasms 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 NSCLC 4 Multiple Myeloma 4 Unspecified Adult Solid Tumor, Protocol Specific 3 Mesothelioma 3 Lymphoma, Mantle-Cell 3 Lymphoma, Large-Cell, Immunoblastic 3 Lymphoma, Follicular 3 Lymphoma, B-Cell, Marginal Zone 3

Interventions

Vinorelbine 1 Temozolomide 1 Radiotherapy 1 Genz-644282 1 Gemcitabine 1 Everolimus 1 Drug Therapy 1 Cisplatin 1 Cilengitide 1 Cetuximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Metatropic dwarfism × Vinorelbine × Clear all

NCT00842712 2017-01-13

CERTO

Merck KGaA, Darmstadt, Germany

Phase 2 Completed

232 enrolled 17 charts

Metatropic dwarfism, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡